此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects

2018年9月25日 更新者:UNEEG Medical A/S
The objective of this pilot trial is to demonstrate the safety and the performance of the Hyposafe hypoglycaemia alarm device before conducting clinical trials in type 1 diabetes patients.

研究概览

地位

完全的

条件

详细说明

  1. Safety: To evaluate safety issues related to implantation and use of the Hyposafe hypoglycaemia alarm device.
  2. Performance: To evaluate the performance of the Hyposafe hypoglycaemia alarm device.
  3. Usability: To obtain information about the subjects use and acceptance of the Hyposafe Hypoglycaemia alarm device.

研究类型

介入性

注册 (实际的)

18

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Esbjerg、丹麦、6800
        • Sydvestjysk Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy subjects
  • Age 18-70 years
  • For female participants: Not pregnant and, if child bearing potential, usage of reliable anti-contraceptive method during the study period

Exclusion Criteria:

  • Severe cardiac disease

    • History of myocardial infarction
    • Cardiac arrhythmia
  • Previous stroke or cerebral haemorrhage and any other structural cerebral disease
  • Active cancer or cancer diagnosis within the past five years
  • Uraemia defined as s-creatinine above 3 times upper reference value
  • Liver disease defined as s-alanine aminotransferase (s-ALAT) above 3 times upper reference interval
  • Epilepsy
  • Use of antiepileptic drugs for any purposes
  • Clinical important hearing impairment
  • Use of active implantable medical device including

    • Pacemaker and Implantable Cardioverter Defibrillator (ICD-unit)
    • Cochlear implant
  • Use of following drugs

    • Chemotherapeutic drugs of any kind
    • Methotrexate
    • Third generation antipsychotic drugs (aripiprazole, quetiapine, clozapine, ziprasidone, paliperidone, risperidone, sertindole, amisulpride, olanzapine)
  • Abuse of alcohol (defined as consumption of > 250g alcohol (in Danish: 21 "genstande")) per week or abuse of any other neuro-active substances
  • Infection at the site of device-implantation
  • Any haemorrhagic disease
  • Diving (snorkel diving allowed) or parachute jumping
  • Patients that are judged incapable to understand the patient information or who are unlikely to complete the investigation for any reason
  • Persons operating MRI scanners.
  • Persons operating handheld transceivers for communication (e.g. within the police, medical, fire, air traffic control, marine or military).
  • Persons working at broadcast stations for television or FM/DAB radio.
  • Persons performing extreme sport.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:设备可行性
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Sydvestjysk Hospital
Investigation of EEG recording with the Hyposafe device
Subcutaneous EEG recorder for EEG measurements

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Performance: EEG Recordings - Impedance
大体时间:1 month
The EEG performance was measured as the mean impedance as a function of time. An impedance value below 5 kOhm is considered very good.
1 month
Performance: EEG Quality
大体时间:1 month
The power spectrum densities from the two modalities were directly compared on an integer scale from -5 to 5, where "-5" signifies that the scalp EEG was of much higher quality than the subcutaneous. "0" means they were of equal quality and "5" means the subcutaneous signal was of much higher quality
1 month
Performance: Continuous EEG
大体时间:1 month
Average time of EEG recordings (hours/day)
1 month

次要结果测量

结果测量
措施说明
大体时间
Usability: Reported Discomfort During Day While Wearing the Device
大体时间:1 month
The discomfort during the day was recorded by the study subject every day wearing the device. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: There has been no discomfort while wearing the HypoSafe device during day?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).
1 month
Usability: Reported Discomfort During Night While Wearing the Device
大体时间:1 month
The discomfort during the night was recorded by the study subject every night wearing the device. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: There has been no discomfort while wearing the HypoSafe device during night?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).
1 month
Usability: Reported Discomfort Related to the Implant in the Beginning of the Study
大体时间:19±4 days after implantation
The discomfort was recorded by the study subjects 19±4 days after implantation. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: I have not experienced any implant discomfort the past two days?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).
19±4 days after implantation
Usability: Reported Discomfort Related to the Implant at the End of the Study
大体时间:51±3 days after implantation
The discomfort was recorded by the study subjects 51±3 days after implantation. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: I have not experienced any implant discomfort the past two days?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).
51±3 days after implantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Birger Thorsteinsson, MD, DMSc、Nordsjællands Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年11月1日

初级完成 (实际的)

2017年1月1日

研究完成 (实际的)

2017年3月1日

研究注册日期

首次提交

2015年3月18日

首先提交符合 QC 标准的

2015年3月27日

首次发布 (估计)

2015年3月30日

研究记录更新

最后更新发布 (实际的)

2018年9月26日

上次提交的符合 QC 标准的更新

2018年9月25日

最后验证

2018年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • Pilot 2_health_v2_August 27th

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Hyposafe device的临床试验

订阅